MedTrace Logo

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-03-15

Study results available
· View outcomes & findings →

Summary

The hypothesis of the current proposal is that chronic pioglitazone therapy will result in improved endothelial function, decreased inflammation, and preservation of renal function in patients with CKD but without diabetes.

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone 30 mg daily for 6 months

DRUG

Placebo

Placebo 30 mg daily for 6 months

DRUG

Nitroglycerin

0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.

Sponsors & Collaborators

Principal Investigators

  • Patricia M. Best, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2009-01-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00586261 on ClinicalTrials.gov